PBS-Bio inks deals to speed up cancer drug development
Predictive Biomarker Sciences (PBS-Bio) is collaborating with ENDECE, Revalesio and Unibioscreen to help bring new cancer drugs to the marketplace faster.
Archives for October 20, 2010
Horizon and Cylene to better patient selection in cancer drug development deal
Horizon Discovery will use its X-MAN human disease cell line models to identify patients likely to benefit from Cylene Pharmaceuticals’ candidate cancer drug, CX-4945.
FDA adverse event revisions a positive step, says CEO
Revision to FDA guidance on adverse event reporting is a positive step and forms part of a welcome increased focus on safety, says the CEO of Prism Ideas.
Reaxa spin-off ADC Biotechnology talks new processing tech
A developmental purification system for Antibody-Drug-Conjugates will be launched by ADC Biotechnology (ADBC), a spin off from Reaxa, which promises reduced manufacturing costs for “magic bullet” cancer drugs.
iGPS launches ‘fungicide-free’ plastic pallet rental service
iGPS is offering what it claims is the world’s first pallet rental service to supply plastic pallets with embedded radio frequency identification (RFID) tags to the pharmaceutical and life sciences industries.
Access & Lotus move to protect oral delivery tech IP
Access Pharmaceuticals and Lotus Pharmaceuticals have both moved to protect their oral delivery technologies with patents.
New industrial CPO grade launched to meet drug sector demand
Bio-Research Products (BRP) launches lower cost, industrial chloroperoxidase (CPO) for organic syntheses in pharmaceutical manufacturing.
WHO begins prequalification programme for selected APIs
The WHO is today initiating a pilot prequalification programme for selected APIs used in drugs for HIV and related diseases, antimalarials and anti-tuberculosis medications.
Westat streamlines trial documents with digital signature tech
Westat says digital signature system streamlines trial operations by uniting people signing regulatory documents worldwide.
SCM to examine Japanese fill-finish market
SCM Pharma will examine Japanese drug industry demand as part of UK Trade & Investment (UKTI) mission to the country at the end of the month..